Suprefort

Suprefort is a peptide bioregulator developed by Professor Khavinson's research group, derived from pancreatic tissue, targeting pancreatic aging and the age-related decline in glucose metabolism.

The pancreas undergoes substantial functional changes with aging: beta cell mass and insulin-secretory capacity decline, first-phase insulin secretion becomes blunted (an early marker of T2D development), and glucagon suppression after meals is impaired. These changes contribute directly to the near-universal age-related increase in fasting glucose and the dramatically increased T2D risk after age 65.

In the Khavinson bioregulator framework, Suprefort contains short regulatory peptides from pancreatic tissue that are proposed to support gene expression in pancreatic islet cells — primarily beta cells (insulin-secreting) but potentially also ductal cells (pancreatic stem cell niche) and acinar cells (exocrine function).

Research from the Khavinson group has included studies in animal models of diabetes showing improved glucose tolerance after treatment with pancreatic tissue peptide bioregulators, and clinical observational studies in elderly patients showing improvements in glucose metabolism markers.

Suprefort occupies a unique niche in the Khavinson bioregulator system because the pancreas is both an exocrine and endocrine organ — its anti-aging relevance spans digestive function (exocrine enzyme secretion) and metabolic regulation (insulin/glucagon). It is often combined with metabolic anti-aging interventions (Epithalon, MOTS-c, NAD+ precursors) in comprehensive longevity protocols.